A Proteomics-Based Assessment of Inflammation Signatures in Endotoxemia.


Journal

Molecular & cellular proteomics : MCP
ISSN: 1535-9484
Titre abrégé: Mol Cell Proteomics
Pays: United States
ID NLM: 101125647

Informations de publication

Date de publication:
2021
Historique:
received: 01 09 2020
revised: 02 11 2020
accepted: 07 12 2020
pubmed: 9 12 2020
medline: 15 3 2022
entrez: 8 12 2020
Statut: ppublish

Résumé

We have previously shown that multimers of plasma pentraxin-3 (PTX3) were predictive of survival in patients with sepsis. To characterize the release kinetics and cellular source of plasma protein changes in sepsis, serial samples were obtained from healthy volunteers (n = 10; three time points) injected with low-dose endotoxin (lipopolysaccharide [LPS]) and analyzed using data-independent acquisition MS. The human plasma proteome response was compared with an LPS-induced endotoxemia model in mice. Proteomic analysis of human plasma revealed a rapid neutrophil degranulation signature, followed by a rise in acute phase proteins. Changes in circulating PTX3 correlated with increases in neutrophil-derived proteins following LPS injection. Time course analysis of the plasma proteome in mice showed a time-dependent increase in multimeric PTX3, alongside increases in neutrophil-derived myeloperoxidase (MPO) upon LPS treatment. The mechanisms of oxidation-induced multimerization of PTX3 were explored in two genetic mouse models: MPO global knock-out (KO) mice and LysM Cre Nox2 KO mice, in which NADPH oxidase 2 (Nox2) is only deficient in myeloid cells. Nox2 is the enzyme responsible for the oxidative burst in neutrophils. Increases in plasma multimeric PTX3 were not significantly different between wildtype and MPO or LysM Cre Nox2 KO mice. Thus, PTX3 may already be stored and released in a multimeric form. Through in vivo neutrophil depletion and multiplexed vascular proteomics, PTX3 multimer deposition within the aorta was confirmed to be neutrophil dependent. Proteomic analysis of aortas from LPS-injected mice returned PTX3 as the most upregulated protein, where multimeric PTX3 was deposited as early as 2 h post-LPS along with other neutrophil-derived proteins. In conclusion, the rise in multimeric PTX3 upon LPS injection correlates with neutrophil-related protein changes in plasma and aortas. MPO and myeloid Nox2 are not required for the multimerization of PTX3; instead, neutrophil extravasation is responsible for the LPS-induced deposition of multimeric PTX3 in the aorta.

Identifiants

pubmed: 33288685
pii: S1535-9476(20)35135-5
doi: 10.1074/mcp.RA120.002305
pmc: PMC7950208
pii:
doi:

Substances chimiques

Blood Proteins 0
Lipopolysaccharides 0
Proteome 0
Peroxidase EC 1.11.1.7
NADPH Oxidase 2 EC 1.6.3.-

Types de publication

Comparative Study Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

100021

Subventions

Organisme : Department of Health
ID : CS-2016-16-011
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/16/14/32397
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH/16/3/32406
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH/1999001/11735
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RE/18/2/34213
Pays : United Kingdom

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest King's College London has filed and licensed a patent application with regard to using PTX3 multimers as a biomarker in sepsis. R. F. S. reports research grants and personal fees from AstraZeneca, Cytosorbents, GlyCardial Diagnostics, and Thromboserin and personal fees from Bayer, Bristol Myers Squibb/Pfizer, Hengrui, Idorsia, Intas Pharmaceuticals, PhaseBio, Portola, and Sanofi Aventis.

Auteurs

Sean A Burnap (SA)

King's College London British Heart Foundation Centre, School of Cardiovascular Medicine and Sciences, London, United Kingdom.

Ursula Mayr (U)

King's College London British Heart Foundation Centre, School of Cardiovascular Medicine and Sciences, London, United Kingdom.

Manu Shankar-Hari (M)

School of Immunology and Microbial Sciences, King's College London and Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.

Friederike Cuello (F)

Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Centre, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Mark R Thomas (MR)

Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom.

Ajay M Shah (AM)

King's College London British Heart Foundation Centre, School of Cardiovascular Medicine and Sciences, London, United Kingdom.

Ian Sabroe (I)

Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, United Kingdom.

Robert F Storey (RF)

Cardiovascular Research Unit, Department of Infection Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom.

Manuel Mayr (M)

King's College London British Heart Foundation Centre, School of Cardiovascular Medicine and Sciences, London, United Kingdom. Electronic address: manuel.mayr@kcl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH